Comparative study of commercially available procarboxypeptidase U (thrombin-activatable fibrinolysis inhibitor) assays.
Heylen E, Willemse JL, Hendriks DF
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine the effects of patient genotype and assay type on measurement of proCPU in plasma from healthy individuals. Genotype was determined using fresh blood specimens prior to separation and storage of the plasma at -80 degrees C.
Summary of Findings
The authors report that proCPU levels measured with each kit were as expected for a healthy population and were dependent on genotype, with the exception of the Actichrom TAFI activity assay which measured levels that were 3.5 fold higher than expected. There was a high degree of correlation between proCPU levels measured with HPLC and those measured with Asserachrom TAFI (r = 0.896), Zymutest proTAFI (r = 0.850), Actichrom TAFI (r = 0.806) and Pefakit TAFI (r = 0.916) kits, regardless of genotype. In contrast, proCPU levels measured with the Visulize TAFI kit had a high degree of overall correlation with HPLC levels (r = 0.823), but in specimens that were homozygous for CPU isoleucine (Ile)325, the levels were lower than when measured by HPLC. Less correlation with proCPU levels measured by HPLC was found using the Imuclone TAFI (r = 0.524) and Zymutest TAFI (r = 0.674) kits due to lower detection of proCPU Ile 325.
Biospecimens
FluidBloodFluidPlasmaPreservation Types
FrozenDiagnoses
NormalPlatforms
DNASNP assayProteinELISAProteinHPLCProteinEnzyme assayPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Patient genotype Homozygous Carboxypeptidase U Ile 325Homozygous Carboxypeptidase U Thr 325Enzyme assay Specific Detection method Actichrome TAFIPefakit TAFIELISA Specific Detection method Asserachrom TAFIImuclone TAFIVisulize TAFIZymutest TAFIZymutest proTAFIHPLC Specific Technology platform Activity assayELISA